Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project.
De Gregorio A, Nagel G, Möller P, Rempen A, Schlicht E, Fritz S, Flock F, Kühn T, Thiel F, Felberbaum R, Ebner F, De Gregorio N, Friedl TWP, Wiesmüller L, Kuhn P, Schmitt M, Janni W, Rothenbacher D, Huober J. De Gregorio A, et al. Among authors: kuhn p, kuhn t. Arch Gynecol Obstet. 2020 Jan;301(1):273-281. doi: 10.1007/s00404-019-05395-3. Epub 2019 Nov 28. Arch Gynecol Obstet. 2020. PMID: 31781887
Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients.
Wolters R, Wöckel A, Janni W, Novopashenny I, Ebner F, Kreienberg R, Wischnewsky M, Schwentner L; BRENDA Study Group. Wolters R, et al. Breast Cancer Res Treat. 2013 Dec;142(3):579-90. doi: 10.1007/s10549-013-2772-y. Epub 2013 Nov 21. Breast Cancer Res Treat. 2013. PMID: 24258258
Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II.
Schwentner L, Van Ewijk R, Kühn T, Flock F, Felberbaum R, Blettner M, Kreienberg R, Janni W, Wöckel A, Singer S. Schwentner L, et al. Among authors: kuhn t. Support Care Cancer. 2016 Jun;24(6):2759-66. doi: 10.1007/s00520-016-3088-3. Epub 2016 Jan 27. Support Care Cancer. 2016. PMID: 26816089
Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II.
Stüber T, van Ewijk R, Diessner J, Kühn T, Flock F, Felberbaum R, Blettner M, Kreienberg R, Janni W, Wöckel A, Singer S, Schwentner L. Stüber T, et al. Among authors: kuhn t. Breast Cancer. 2017 Mar;24(2):281-287. doi: 10.1007/s12282-016-0701-8. Epub 2016 May 19. Breast Cancer. 2017. PMID: 27193566
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).
Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SY, Dall P, Denkert C, Fasching PA, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Liedtke C. Untch M, et al. Among authors: kuhn t. Geburtshilfe Frauenheilkd. 2017 Jun;77(6):633-644. doi: 10.1055/s-0043-111601. Epub 2017 Jun 28. Geburtshilfe Frauenheilkd. 2017. PMID: 28769126 Free PMC article.
Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: Results from the prospective multicenter BRENDA II study.
Leinert E, Schwentner L, Blettner M, Wöckel A, Felberbaum R, Flock F, Kühn T, Denkinger MD, Janni W, Kreienberg R, Singer S; BRENDA Study Group. Leinert E, et al. Among authors: kuhn t. Breast J. 2019 May;25(3):386-392. doi: 10.1111/tbj.13231. Epub 2019 Apr 3. Breast J. 2019. PMID: 30945393 Clinical Trial.
845 results